Circulating cells

Manager
Dr. Françoise Farace
Email

Secretariat : 
Stéphanie Quimbert
+33 (0)1 42 11 56 30
E-mail

Molecular Medecine Building

Frise Banner: 
Circulating cells

Circulating cells section

This section specialises in exploration of circulating tumour cells (CTC) and circulating endothelial or endothelial progenitor cells (CEC & CEP).  It is also engaged in assessment of plasma and serum protein markers such as angiogenic factors:

  • Study of circulating endothelial cells (CEC), endothelial progenitor cells (CEP) and circulating tumour cells (CTC) in therapeutic trials and academic and commercial studies
  • Research on the clinical relevance of these cells (eg. PHRC [hospital programme of clinical research] CTC phase I, therapeutic trials)
  • R&D activity: evaluation of new methods of detection of CTC (Iset®; prototyping of micro fluidic systems…); development of original methods of identification and phenotypic and molecular characterisation of CTC using immunofluorescence, FISH (looking for amplification and rearrangement) or laser microdissection of single cells (looking for mutations).
  • Specific research projects:
    • Phenotypic and molecular characterisation of CTCs in non-small cell lung cancers (project on ALK and ROS1 gene rearrangements and EGFR mutations); in prostate cancer (amplification of AR gene, rearrangement of ERG); and breast cancer (amplification of HER2)
    • Study of mechanisms of resistance in the CTC to targeted therapy (in particular to ALK inhibitors)
    • Development of mouse models with a view to establishing the primary diagnosis from CTCs and characterising the metastatic potential of CTC sub-populations. 
Catégorie de la page: